Inappropriate ADH Syndrome: Clinical Trials

7 trials for Inappropriate ADH Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated. 7 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Terminated 2
Phase 33Completed 3
Phase 11Completed 1

Follow Inappropriate ADH Syndrome: new trials by email Literature Review of Inappropriate ADH Syndrome trials Research Report on Inappropriate ADH Syndrome

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Urea for Chronic Hyponatremia
Urea - Hyponatremia, Inappropriate ADH Syndrome
Phase 2TerminatedHelbert Rondon Berrios, MD, MS22021-12-282024-05-20
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland172017-12-152021-12-13
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
Empagliflozin, Placebo - SIADH
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland882016-09-052019-06-13
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland152016-03-012016-08-10
A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
tolvaptan - Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Phase 1 / Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.302013-11-012016-05-16
Tolvaptan for In-hospital Hyponatremia
Tolvaptan, Standard therapy - Hyponatremia
Phase 2TerminatedMario Negri Institute for Pharmacological Research32011-06-012016-12-15
Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
satavaptan (SR121463B) - Syndrome of Inappropriate ADH (SIADH) Secretion, Hyponatremia
Phase 2CompletedSanofi352001-06-012008-06-17

Narrower conditions

Hyponatremia (6)  ·  Diabetes Insipidus (1)

Broader conditions

Brain Diseases (7)  ·  Central Nervous System Diseases (7)  ·  Endocrine System Diseases (7)  ·  Hypothalamic Diseases (7)  ·  Metabolic Diseases (7)  ·  Nervous System Diseases (7)  ·  Nutritional and Metabolic Diseases (7)  ·  Pituitary Diseases (7)  ·  Water-Electrolyte Imbalance (7)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Kidney Diseases (1)  ·  Male Urogenital Diseases (1)  ·  Urogenital Diseases (1)  ·  Urologic Diseases (1)

Interventions

empagliflozin (3)  ·  Tolvaptan (2)  ·  Standard of Care (1)  ·  Tablets (1)  ·  Urea (1)  ·  satavaptan (1)

Sponsors

University Hospital, Basel, Switzerland (3)  ·  Helbert Rondon Berrios, MD, MS (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)  ·  Sanofi (1)

Countries

Switzerland (3)  ·  Germany (2)  ·  Hungary (2)  ·  Belgium (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)  ·  Italy (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Helbert Rondon Berrios, MD. MS (1)  ·  Mirjam Christ-Crain, Prof. (1)  ·  Mirjam Christ-Crain, Prof. Dr. MD (1)  ·  Mirjam Christ-Crain, Prof., MD (1)

Results publications

PMID 34412521, PMID 36396331, PMID 37098131, PMID 42522233

NIH funding

2015 (1), 2017 (1), R21DK122023 (1)